Ménière’s Vestibular Balance: Inner-Ear Science, Safety, and a 9-Phase Wellness Program Guide

by | Aug 11, 2026 | Uncategorized | 0 comments

Ménière’s Vestibular Balance: Inner-Ear Science, Safety, and a 9-Phase Wellness Program Guide

Quick answer: Ménière’s disease is a medical inner-ear condition involving episodic vertigo, fluctuating hearing changes, tinnitus, and/or ear fullness. It deserves assessment by an ENT clinician or audiologist. The Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics is best understood as an experimental wellness and relaxation routine, not a diagnosis, treatment, or replacement for medical care. Its research references explain elements of the design; they do not prove that the app, iTorus, headphones, haptics, or the combined setup treats Ménière’s disease.

This guide separates what is established from what is not. It explains inner-ear and vestibular science, the research context behind the nine-phase design, the program’s spectral structure, safe iTorus-plus-headphones and iTorus-alone workflows, topic-appropriate affirmations, and a conservative 30-day routine template. The central rule is simple: never use a wellness session to push through dangerous dizziness, sudden hearing change, or a new neurologic symptom.

This article uses the exact primary program link supplied for this guide: Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics.

Cinematic anatomical-inspired illustration of a translucent cochlea and semicircular canals with subtle neural pathways
Inner-ear anatomy is complex: the cochlea supports hearing, while the vestibular apparatus helps the brain interpret motion and position. This image is illustrative and does not depict a treatment.

What Ménière’s Disease Is—and Why “Balance” Is Not Just About the Ear

Ménière’s disease is a disorder of the inner ear. Its hallmark symptom cluster includes spontaneous vertigo attacks, fluctuating sensorineural hearing loss, tinnitus, and aural fullness or pressure. The 2020 clinical guideline defines definite Ménière’s disease using both the attack pattern and documented hearing findings; it is not diagnosed from dizziness alone [1]. The National Institute on Deafness and Other Communication Disorders (NIDCD) explains that symptoms are associated with altered fluid regulation in the labyrinth, including the phenomenon called endolymphatic hydrops, but the condition is multifactorial and its underlying causes are not fully settled [2].

The labyrinth includes the cochlea, which transduces sound, plus the vestibule and semicircular canals, which contribute to balance. Endolymph movement helps sensory receptors signal body position and movement to the brain. These signals are then interpreted through vestibular nerve, brainstem, cerebellar, ocular-motor, autonomic, and musculoskeletal systems. That is why a vertigo episode can involve spinning, nausea, sweating, eye-movement changes, anxiety, fatigue, and a temporary loss of confidence in movement—not simply an “ear problem” [2] [8].

Evidence map showing inner-ear anatomy, endolymphatic hydrops association, vestibular signaling, clinical care context, wellness design, and evidence limits
Established anatomy and clinical context are shown separately from the program’s wellness design. A visual map of a signal is not evidence that it changes the biology of Ménière’s disease.

What the Research Actually Supports

The most responsible way to discuss a program for a condition-associated topic is to identify the intervention actually studied. A study of electrical auricular vagus-nerve stimulation is not a study of a consumer PEMF coil. A trial of relaxing music is not proof of tinnitus treatment by binaural audio. A study of a medication is not proof that a proprietary substance-reference layer reproduces that medicine. Those distinctions matter.

Research area What the evidence supports What it does not establish for this program
Clinical definition and care Ménière’s disease is defined by a specific symptom and hearing-test pattern, and guideline management includes diagnostic work-up, education, lifestyle/medical options, and escalation when appropriate [1]. That a wellness audio, haptic, or PEMF program diagnoses or manages the disease.
Electrical taVNS A 2023 single-center, single-blind randomized trial studied electrical transcutaneous auricular vagus-nerve stimulation plus betahistine; its reported outcomes favored that protocol over sham plus betahistine at 12 weeks [3]. That a 9-phase audio file, headphones, haptic vibration, or iTorus is taVNS or produces the same response.
Music and binaural audio In a 30-person chronic-tinnitus trial, both relaxing-music groups improved; music plus an alpha binaural layer was not broadly superior to music alone, although two follow-up subscales differed [4]. That binaural audio treats tinnitus, Ménière’s disease, or hearing loss.
Inner-ear fluid biology Human endolymphatic-sac tissue research found higher AQP2 expression density in a Ménière’s group, while several other investigated targets did not differ significantly [5]. That this program changes AQP2, vasopressin signaling, potassium transport, endolymph volume, or hydrops.
Vestibular rehabilitation A 2023 meta-analysis found immediate-term quality-of-life improvement favoring vestibular rehabilitation, but it included only three trials, had high heterogeneity, and found high risk of bias [6]. That self-directed exercises or a wellness session should be used during an acute vertigo attack. Rehabilitation should be clinician-guided for chronic imbalance.
PEMF science PEMF research shows that biological responses vary materially with waveform, field intensity, frequency, duration, and cell type [7] [12]. That findings from another device, field dose, tissue model, or clinical indication transfer to the iTorus or this specific program.

The Program’s Spectral Image: What You Can See—and What You Cannot Conclude

A spectrum is a visual description of signal content over time. It can reveal changing bands, density, transitions, sustained carriers, and the visual shape of an exit. It does not measure the coil’s magnetic flux density at the body, establish the dose received by tissue, or demonstrate a clinical effect.

Pitch spectral view of the Ménière’s Vestibular Balance and Inner Ear BioMatrix 9-Phase program showing sustained bands, staged blocks, and a fading ending
Supplied spectral view of the 33:33 program. It displays a persistent upper anchor, staged lower and mid-band blocks, purposeful transitions, and a simplified fading exit. The image is a signal-architecture observation, not medical efficacy evidence.

The supplied pitch view shows a relatively persistent narrow higher band across much of the timeline, while denser blocks appear and recede in the lower-to-mid display bands. The lower visual energy is broad rather than frozen: its intensity changes across distinct sections. In the later segment, the image simplifies and fades rather than ending abruptly. That visual pattern is consistent with a deliberately phased audio architecture: a stable orientation reference, changing layered content, then a quieter return to stillness.

It would be inaccurate, however, to infer a biological result from those colors or to identify proprietary substance values from a spectrogram. The appropriate conclusion is more modest: this is not a single static audio loop. It is a changing 33:33 signal design whose visual structure corresponds to the stated nine-phase journey.

The 9-Phase BioPhi-Harmonic Journey

Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics is organized as a 33:33 sequence. The public-facing rationale is not that each phase “fixes” a part of the ear. Rather, the program changes its signal topology over time so the listening and hardware experience moves from orientation into a denser middle passage and then toward a quieter exit.

Vertical nine-phase journey from orientation through vestibular-auditory integration to zero-point integration
The nine-phase sequence is an experimental wellness design journey—not a clinical treatment pathway.
Phase group Phases Public design intent Responsible interpretation
Entry 1. Orientation Anchor
2. Bilateral Vestibular Field
3. Inner-Ear Calm Matrix		 Create a predictable, less abrupt opening; introduce bilateral and homeostasis-themed signal layers. A predictable seated listening ritual may feel easier to tolerate for some people. It is not evidence of vestibular correction.
Integration 4. Alpha Auditory Coherence
5. Vagal Settling Field
6. Polarity-to-Torus Transition
7. Vestibular-Auditory Integration		 Use paced sensory design, changing stereo geometry, and the session’s densest layered passage. The design references relevant research domains, but it does not replicate electrical vagus stimulation or prescribed rehabilitation.
Exit 8. Reorientation & Stabilization
9. Zero-Point Integration		 Reduce complexity and return toward centered quiet. A deliberate wind-down may support a calmer post-session transition. No disease-specific outcome is established.

Why a Dynamic Program Is Not the Same as a “Disease Frequency”

Internet frequency lists often suggest that a single static number can be selected for a diagnosis. That is not a sound clinical model for Ménière’s disease. The condition involves fluctuating hearing and vestibular symptoms, individual triggers, fluid-regulation hypotheses, neural processing, and a wide range of clinical presentations. No credible evidence shows that a generic static “Ménière’s frequency” diagnoses, eliminates, or reverses the condition.

The engineering case for a multi-phase program is simpler and more defensible: the audible and haptic experience changes in intensity, density, stereo relationship, and transition pattern rather than repeating a short unchanging loop. This may make the session subjectively more varied. It is not established that such changes prevent “cellular adaptation” in Ménière’s disease or make the program clinically superior to a static signal. That claim would require a direct comparative trial of the exact devices, exposure parameters, and clinical outcomes.

Triple Modality: iTorus, Haptic, and Binaural Audio—Without Overclaiming

The platform can be experienced through three distinct delivery layers. Each layer has a different practical function, and none should be represented as an approved treatment for Ménière’s disease. The safest framing is to treat the combination as a structured wellness ritual: a consumer electromagnetic device used according to its instructions, optional body vibration, and careful audio listening.

Layer What the user experiences What can responsibly be said What cannot be claimed
PEMF / iTorus A consumer wellness coil operating through the manufacturer-supported connection and placement method. PEMF parameters matter; external studies cannot be assumed to apply to another device [7]. That the coil treats hydrops, restores hearing, stimulates the vagus nerve clinically, or duplicates a study on a different device.
Wired headphones Stereo audio, including the program’s binaural design, at a low-to-moderate volume. Headphones are required to perceive a binaural left-right difference. Relaxing audio may support a personally calming context. That headphones cure tinnitus or “reset” vestibular pathways.
Haptic option Optional low, comfortable whole-body vibration through a compatible device. Vibration changes body sensation and may be used as an optional grounding cue. That vibration mobilizes inner-ear fluid or treats balance dysfunction.
iTorus alone Coil-based use without headphones. This is a separate consumer-wellness mode for people who prefer no audio. That the binaural layer is being delivered without stereo headphones.
Safety decision flow for using the Ménière’s 9-phase program with iTorus and wired headphones or iTorus alone
Use this as a safety and setup flow, not as a medical decision tree. New or severe symptoms require medical assessment rather than a higher-intensity session.

Why These Substance Themes Are Included—Without Treating Them as Frequencies

The architecture includes proprietary internal reference layers associated with several medicines that appear in the wider clinical literature around vertigo, diuretics, or endolymphatic-hydrops management. The presence of a substance theme does not mean that the program contains the drug, reproduces its pharmacology, or can replace it. Specific proprietary substance-frequency values are intentionally not disclosed.

  • Buclizine: This is included as a symptom-management pharmacology theme relevant to dizziness/nausea language. It should never be interpreted as a substitute for clinician-directed medication.
  • Hydrochlorothiazide and triamterene: These appear in the conventional diuretic-management context. A placebo-controlled crossover study of the combination reported reduced vestibular complaints in its participant group, while hearing and tinnitus did not significantly change [9]. That supports discussion of the clinical context—not a claim that a signal layer behaves like a diuretic.
  • Acetazolamide: A small imaging series described symptom improvement and partial or complete hydrops reversal in some participants receiving acetazolamide [10]. The study does not validate a wellness signal as acetazolamide, nor does it establish that this program reverses hydrops.

The responsible interpretation is therefore: the program’s internal references are experimental design themes chosen because their associated substances have clinical relevance in the topic area. They are not molecular resonances, medication equivalents, or treatment instructions.

How to Use iTorus With Headphones—or iTorus Alone

Mode A: iTorus + wired stereo headphones

  1. Open frequencyhealing.app and select Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics.
  2. Set up the iTorus i2 or iTorus i5 only through the manufacturer-supported connection and placement instructions. Do not improvise wiring and do not increase output in pursuit of a stronger effect.
  3. Use wired stereo headphones at a low-to-moderate, comfortable volume. The purpose is to make the stereo audio perceptible; loudness is not a therapeutic dose. Do not compensate for hearing loss by turning the volume up.
  4. Remain seated, reclined, or lying down. Keep water, a phone, and a stable route to rest nearby. Avoid walking, driving, stairs, bathing, or food preparation during the session.
  5. Use a simple cue: notice breathing and support from the chair or bed. If dizziness, nausea, ear discomfort, tinnitus distress, faintness, headache, or agitation rises, stop instead of pushing through.

Mode B: iTorus alone

  1. Open the same Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics program in frequencyhealing.app.
  2. Use the iTorus only in the way the manufacturer permits. Select a comfortable, conservative setup and remain in the same fall-safe position.
  3. Because there are no stereo headphones, do not call this a binaural session. Treat it as a coil-based, quiet wellness routine with the same stop rules and no claim of a clinical vestibular effect.
  4. Afterward, wait until you feel steady before standing. Make a short reflection note rather than trying to interpret every sensation as a treatment response.

30-Day Ménière’s Vestibular Balance Wellness Routine

Important: This is a 30-day wellness-routine template, not a medical protocol. There is no clinical trial showing that daily use of this exact program or iTorus setup treats Ménière’s disease. The value of the schedule is predictability, conservative setup, symptom-aware pacing, and better questions for a clinician—not “pushing through” symptoms. On any day, skip the session if you are unwell or if prior use increased symptoms. Every day below links the exact primary program, as requested.

Day Primary program Mode and pacing Affirmation After-session note
1 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; low volume; seated/reclined. I can pause, sit safely, and give my senses a quiet moment. Rate comfort before/after; stop if worse.
2 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; same safe position; no binaural claim. I choose steadiness over intensity. Note environment and position.
3 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; keep the same comfortable volume. I let predictable routines support calm attention. Note whether sound felt comfortable.
4 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; do not increase device output. I am allowed to stop when my body asks for rest. Write one sentence on tolerance.
5 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; low-to-moderate volume only. I can meet this moment with gentleness. Note sleep quality without assigning cause.
6 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; quiet room; remain still. My safety comes first. Log any reason you paused or skipped.
7 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics Choose the better-tolerated mode from Days 1–6. I learn from my experience without forcing a result. Week-1 review: comfort, triggers, questions.
8 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; repeat the safest routine. Consistency can be quiet and uncomplicated. Note the time of day.
9 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; keep identical safety conditions. I respond to my body with patience. Log whether you stopped early.
10 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; confirm volume before start. I protect my hearing by choosing a comfortable volume. Note audio comfort, not “effectiveness.”
11 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; no simultaneous tasks or walking. I can give my senses one task at a time. Note room light and noise level.
12 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; recline if that feels safer. I make room for rest without needing to solve everything. Note comfort after standing slowly.
13 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; manufacturer-guided setup only. I do not need more intensity to practice self-care. Log any symptom change factually.
14 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics Choose the more comfortable mode; skip if symptoms are active. I honor signals that tell me to rest. Week-2 review: pattern, not conclusion.
15 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; familiar position and volume. I can notice my senses without fear or urgency. Log a 0–10 comfort score.
16 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; stay seated through the end and pause before rising. I return to center one breath at a time. Note how long you rested afterward.
17 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; use a stable head position. I choose a calm environment for this practice. Note if head movement felt uncomfortable.
18 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; no headphones needed today. I can make choices that fit today’s capacity. Log why you chose this mode.
19 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; same conservative settings. I welcome steadiness, not perfection. Record sound level as low/medium only.
20 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; stop if ear discomfort or nausea develops. I can stop, rest, and seek support when needed. Note any stop rule used.
21 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics Choose either mode only if the week has been tolerable. I can be observant without assigning a cause. Week-3 review: bring questions to care team.
22 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; only if no concerning symptoms. I can build trust through safe routines. Note a practical support that helped.
23 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; remain in a familiar room. I am allowed to keep this practice simple. Log location and position.
24 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; low volume, no multitasking. I give my attention to one safe moment. Note any distraction that changed comfort.
25 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; use only approved hardware guidance. I respect my body’s need for caution. Log hydration and meal timing neutrally.
26 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones; stop at first meaningful discomfort. I practice awareness, not endurance. Write one objective sentence.
27 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus alone; wait seated for one minute after ending. I move slowly because safety is strength. Note steadiness before rising.
28 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics Choose the more comfortable mode or skip if uncertain. I trust myself to choose the safer option. Week-4 review: list changes to discuss clinically.
29 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics iTorus + wired headphones only if the routine remains comfortable. I can take what is useful and leave what is not. Prepare a concise clinician question list.
30 Ménière’s Vestibular Balance & Inner Ear BioMatrix 9-Phase BioPhi-Harmonic Energetics Choose either mode only if safe; end with two quiet minutes before standing. I continue with care, curiosity, and appropriate clinical support. 30-day summary: tolerance, triggers, and follow-up plan.

What to Expect—and What to Treat as a Stop Signal

The most honest expectations are experiential rather than diagnostic. A person may notice a more deliberate period of stillness, a relaxing auditory routine, a preference for one setup over another, no noticeable change, or sensory sensitivity. Do not interpret a short-term change as proof that the condition has improved or worsened. Instead, record the facts: environment, position, audio level, mode, duration completed, and whether a symptom prompted stopping.

Stop the session and seek appropriate care for sudden hearing loss, new facial weakness or other focal neurological symptoms, severe or unusual headache, fainting, chest pain, persistent vomiting, inability to stand safely, or symptoms meaningfully different from your established pattern. NIDCD and MedlinePlus both emphasize that Ménière’s symptoms can overlap with other conditions and that clinical evaluation matters [2] [8].

Hardware Options and Affiliate Links

Layer Option Practical role in this routine
PEMF iTorus i2 or iTorus i5 Use only as a consumer wellness device and follow the manufacturer’s instructions, connection method, warnings, and contraindications. This article does not establish a Ménière’s-specific effect.
Haptic Woojer Vest 4 — use code EPEMF10 Optional low, comfortable vibrotactile layer for body awareness. Avoid if vibration is uncomfortable or symptom-provoking.
Imprinting iMPrinter Optional ritual/wellness layer. Do not treat imprinted water as a therapy or replacement for normal hydration and clinical care.
Platform frequencyhealing.app Platform access for the program’s audio and signal architecture.

Safety and Clinical-Care Context

Do not begin this program during a severe active vertigo episode if sensory input feels likely to worsen symptoms. Use it only while seated, reclined, or lying down. Never use it while driving, on stairs, walking outdoors, bathing, swimming, cooking over heat, operating machinery, or in any setting where an unexpected loss of balance could lead to injury. Maintain a low-to-moderate headphone volume; significant asymmetrical hearing loss can change how stereo audio is perceived.

Obtain clinician and manufacturer guidance before electromagnetic or strong haptic use if you have a pacemaker, implanted defibrillator, neurostimulator, insulin pump, cochlear implant or another implanted electronic hearing device, pregnancy, seizure sensitivity, serious arrhythmia, recent surgery, or active bleeding. The Cleveland Clinic notes that PEMF research and safety are context-specific; manufacturer directions and medical guidance take precedence [11].

Educational and wellness disclaimer: This article is for educational purposes only. It does not provide medical advice, diagnosis, or treatment, and it does not establish that any program or device will produce a particular result. Do not delay or replace licensed medical care. Consult a qualified healthcare professional for symptoms, medical conditions, pregnancy, implanted electronic devices, medication questions, or any concern about whether PEMF is appropriate for you. Follow the manufacturer’s instructions for every device.

References

  1. Basura, G. J., et al. (2020). Clinical Practice Guideline: Ménière’s Disease. Otolaryngology–Head and Neck Surgery, 162(2 Suppl), S1–S55. PubMed 32267799.
  2. National Institute on Deafness and Other Communication Disorders. (2024). Ménière’s Disease. NIDCD.
  3. Wu, D., et al. (2023). Meniere Disease treated with transcutaneous auricular vagus nerve stimulation combined with betahistine Mesylate: A randomized controlled trial. Brain Stimulation, 16(6), 1576–1584. PubMed 37838094.
  4. Bakhtarikia, S., et al. (2024). Investigating the effectiveness of music therapy combined with binaural beats on chronic tinnitus: A randomized controlled trial. American Journal of Otolaryngology, 45(4), 104308. PubMed 38723376.
  5. Asmar, M.-H., Gaboury, L., & Saliba, I. (2018). Ménière’s Disease Pathophysiology: Endolymphatic Sac Immunohistochemical Study of Aquaporin-2, V2R Vasopressin Receptor, NKCC2, and TRPV4. Otolaryngology–Head and Neck Surgery, 158(4), 721–728. PubMed 29436285.
  6. Rezaeian, A., et al. (2023). The effect of vestibular rehabilitation in Meniere’s disease: a systematic review and meta-analysis of clinical trials. European Archives of Oto-Rhino-Laryngology, 280(9), 3967–3975. PubMed 37341761.
  7. Mansourian, M., & Shanei, A. (2021). Evaluation of Pulsed Electromagnetic Field Effects: A Systematic Review and Meta-Analysis on Highlights of Two Decades of Research In Vitro Studies. BioMed Research International, 2021, 6647497. PubMed 34368353.
  8. MedlinePlus Medical Encyclopedia. (2025). Meniere disease. U.S. National Library of Medicine. MedlinePlus.
  9. van Deelen, G. W., & Huizing, E. H. (1986). Use of a diuretic (Dyazide) in the treatment of Menière’s disease. A double-blind cross-over placebo-controlled study. ORL Journal of Oto-Rhino-Laryngology and Its Related Specialties, 48(5), 287–292. PubMed 3537899.
  10. Sepahdari, A. R., et al. (2016). Endolymphatic Hydrops Reversal following Acetazolamide Therapy: Demonstration with Delayed Intravenous Contrast-Enhanced 3D-FLAIR MRI. American Journal of Neuroradiology, 37(1), 151–154. PubMed 26381561.
  11. Cleveland Clinic. (2024). Pulsed Electromagnetic Field (PEMF) Therapy: What It Is, Benefits & Risks. Cleveland Clinic.
  12. Ross, C. L., et al. (2023). Pulsed electromagnetic field therapy: a systematic review of clinical applications and biological mechanisms. Bioelectromagnetics. PubMed 37510998.

Related Articles